{
    "xml": "<topic id=\"PHP1557\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/tirofiban\" basename=\"tirofiban\" title=\"TIROFIBAN\">\n<title>TIROFIBAN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1018\" namespace=\"/interactions/list-of-drug-interactions/tirofiban\">Tirofiban</xref>\n</p>\n<data name=\"vtmid\">108981004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_872314852\" title=\"Glycoprotein IIb/IIIa inhibitors\">Glycoprotein IIb/IIIa inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP48531\" outputclass=\"indicationsAndDose\" rev=\"1.16\" parent=\"/drugs/tirofiban\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (with angiopraphy planned for 4&#8211;48 hours after diagnosis (initiated under specialist supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 400&#8239;nanograms/kg/minute for 30 minutes, then 100&#8239;nanograms/kg/minute for at least 48 hours (continue during and for 12&#8211;24 hours after percutaneous coronary intervention), maximum duration of treatment 108 hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (within 4 hours of diagnosis) (initiated under specialist supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>25&#8239;micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150&#8239;nanograms/kg/minute for 12&#8211;24 hours, maximum duration of treatment 48 hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">In combination with unfractionated heparin, aspirin, and clopidogrel for reduction of major cardiovascular events in patients with ST-segment elevation myocardial infarction (STEMI) intended for primary percutaneous coronary intervention (PCI) (initiated under specialist supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>25&#8239;micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150&#8239;nanograms/kg/minute for 12&#8211;24 hours, maximum duration of treatment 48 hours.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48566\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/tirofiban\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Abnormal bleeding within 30 days</ph>; <ph outputclass=\"contraindication\">history of aneurysm</ph>; <ph outputclass=\"contraindication\">history of arteriovenous malformation</ph>; <ph outputclass=\"contraindication\">history of haemorrhagic stroke</ph>; <ph outputclass=\"contraindication\">history of intracranial disease</ph>; <ph outputclass=\"contraindication\">history of neoplasm</ph>; <ph outputclass=\"contraindication\">increased INR</ph>; <ph outputclass=\"contraindication\">increased prothrombin time</ph>; <ph outputclass=\"contraindication\">severe hypertension</ph>; <ph outputclass=\"contraindication\">stroke within 30 days</ph>; <ph outputclass=\"contraindication\">thrombocytopenia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48576\" outputclass=\"cautions\" rev=\"1.12\" parent=\"/drugs/tirofiban\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Active peptic ulcer (within 3 months)</ph>; <ph outputclass=\"caution\">acute pericarditis</ph>; <ph outputclass=\"caution\">anaemia</ph>; <ph outputclass=\"caution\">aortic dissection</ph>; <ph outputclass=\"caution\">cardiogenic shock</ph>; <ph outputclass=\"caution\">discontinue if intra-aortic balloon pump necessary</ph>; <ph outputclass=\"caution\">discontinue if thrombolytic therapy necessary</ph>; <ph outputclass=\"caution\">discontinue immediately if serious or uncontrollable bleeding occurs</ph>; <ph outputclass=\"caution\">discontiue if emergency cardiac surgery necessary</ph>; <ph outputclass=\"caution\">elderly</ph>; <ph outputclass=\"caution\">faecal occult blood</ph>; <ph outputclass=\"caution\">haematuria</ph>; <ph outputclass=\"caution\">haemorrhagic retinopathy</ph>; <ph outputclass=\"caution\">low body-weight</ph>; <ph outputclass=\"caution\">major surgery within 3 months (avoid if within 6 weeks)</ph>; <ph outputclass=\"caution\">organ biopsy or lithotripsy within last 2 weeks</ph>; <ph outputclass=\"caution\">puncture of non-compressible vessel within 24 hours</ph>; <ph outputclass=\"caution\">risk of bleeding (within 3 months)</ph>; <ph outputclass=\"caution\">severe heart failure</ph>; <ph outputclass=\"caution\">severe trauma within 3 months (avoid if within 6 weeks)</ph>; <ph outputclass=\"caution\">traumatic or protracted cardiopulmonary resuscitation within last 2 weeks</ph>; <ph outputclass=\"caution\">uncontrolled severe hypertension</ph>; <ph outputclass=\"caution\">vasculitis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48525\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/tirofiban\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (tirofiban).</p>\n<p>Concomitant drugs that increase risk of bleeding (including within 48 hours of thrombolytic administration).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48495\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/tirofiban\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bleeding manifestations</ph>; <ph outputclass=\"sideEffect\">fever</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">reversible thrombocytopenia</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48522\" outputclass=\"pregnancy\" parent=\"/drugs/tirofiban\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48591\" outputclass=\"breastFeeding\" parent=\"/drugs/tirofiban\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48544\" outputclass=\"hepaticImpairment\" parent=\"/drugs/tirofiban\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in mild to moderate liver disease.</p>\n<p>Avoid in severe liver disease&#8212;increased risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48507\" outputclass=\"renalImpairment\" parent=\"/drugs/tirofiban\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Use half normal dose if eGFR less than 30&#8239;mL/minute/ 1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Increased risk of bleeding.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p>Monitor carefully if eGFR less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48460\" outputclass=\"monitoringRequirements\" parent=\"/drugs/tirofiban\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor platelet count, haemoglobin and haematocrit before treatment, 2&#8211;6 hours after start of treatment and then at least once daily.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48607\" outputclass=\"directionsForAdministration\" rev=\"1.17\" parent=\"/drugs/tirofiban\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>For <i>intravenous infusion</i> (<i>Aggrastat</i>\n<tm tmtype=\"reg\"/>), give continuously in Glucose 5% or Sodium chloride 0.9%. Withdraw 50&#8239;mL infusion fluid from 250&#8239;mL bag and replace with 50&#8239;mL tirofiban concentrate (250&#8239;micrograms/mL) to give a final concentration of 50&#8239;micrograms/mL.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1557-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tirofiban\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77073\" title=\"Infusion\" namespace=\"/drugs/tirofiban/infusion\">Infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77064\" title=\"Solution for infusion\" namespace=\"/drugs/tirofiban/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78144\" namespace=\"/treatment-summaries/acute-coronary-syndromes\" title=\"Acute coronary syndromes\" count=\"2\" rel=\"backlink\">Acute coronary syndromes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78186\" namespace=\"/treatment-summaries/antiplatelet-drugs\" title=\"Antiplatelet drugs\" count=\"3\" rel=\"backlink\">Antiplatelet drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1018\" namespace=\"/interactions/list-of-drug-interactions/tirofiban\" title=\"Tirofiban\" count=\"1\" rel=\"link\">Tirofiban</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77073\" namespace=\"/drugs/tirofiban/infusion\" title=\"Infusion\" count=\"1\" rel=\"link\">Infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77064\" namespace=\"/drugs/tirofiban/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP1557",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/tirofiban",
    "basename": "tirofiban",
    "title": "TIROFIBAN",
    "interactants": [
        {
            "id": "bnf_int_1018",
            "label": "Tirofiban"
        }
    ],
    "vtmid": "108981004",
    "drugClassification": [
        "Glycoprotein IIb/IIIa inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (with angiopraphy planned for 4&#8211;48 hours after diagnosis (initiated under specialist supervision)",
                        "html": "In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (with angiopraphy planned for 4&#8211;48 hours after diagnosis (initiated under specialist supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 400 nanograms/kg/minute for 30 minutes, then 100 nanograms/kg/minute for at least 48 hours (continue during and for 12&#8211;24 hours after percutaneous coronary intervention), maximum duration of treatment 108 hours.",
                        "html": "<p>Initially 400&#8239;nanograms/kg/minute for 30 minutes, then 100&#8239;nanograms/kg/minute for at least 48 hours (continue during and for 12&#8211;24 hours after percutaneous coronary intervention), maximum duration of treatment 108 hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (within 4 hours of diagnosis) (initiated under specialist supervision)",
                        "html": "In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (within 4 hours of diagnosis) (initiated under specialist supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "25 micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150 nanograms/kg/minute for 12&#8211;24 hours, maximum duration of treatment 48 hours.",
                        "html": "<p>25&#8239;micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150&#8239;nanograms/kg/minute for 12&#8211;24 hours, maximum duration of treatment 48 hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "In combination with unfractionated heparin, aspirin, and clopidogrel for reduction of major cardiovascular events in patients with ST-segment elevation myocardial infarction (STEMI) intended for primary percutaneous coronary intervention (PCI) (initiated under specialist supervision)",
                        "html": "In combination with unfractionated heparin, aspirin, and clopidogrel for reduction of major cardiovascular events in patients with ST-segment elevation myocardial infarction (STEMI) intended for primary percutaneous coronary intervention (PCI) (initiated under specialist supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "25 micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150 nanograms/kg/minute for 12&#8211;24 hours, maximum duration of treatment 48 hours.",
                        "html": "<p>25&#8239;micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150&#8239;nanograms/kg/minute for 12&#8211;24 hours, maximum duration of treatment 48 hours.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Abnormal bleeding within 30 days",
                "html": "Abnormal bleeding within 30 days"
            },
            {
                "type": "contraindications",
                "textContent": "history of aneurysm",
                "html": "history of aneurysm"
            },
            {
                "type": "contraindications",
                "textContent": "history of arteriovenous malformation",
                "html": "history of arteriovenous malformation"
            },
            {
                "type": "contraindications",
                "textContent": "history of haemorrhagic stroke",
                "html": "history of haemorrhagic stroke"
            },
            {
                "type": "contraindications",
                "textContent": "history of intracranial disease",
                "html": "history of intracranial disease"
            },
            {
                "type": "contraindications",
                "textContent": "history of neoplasm",
                "html": "history of neoplasm"
            },
            {
                "type": "contraindications",
                "textContent": "increased INR",
                "html": "increased INR"
            },
            {
                "type": "contraindications",
                "textContent": "increased prothrombin time",
                "html": "increased prothrombin time"
            },
            {
                "type": "contraindications",
                "textContent": "severe hypertension",
                "html": "severe hypertension"
            },
            {
                "type": "contraindications",
                "textContent": "stroke within 30 days",
                "html": "stroke within 30 days"
            },
            {
                "type": "contraindications",
                "textContent": "thrombocytopenia",
                "html": "thrombocytopenia"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Active peptic ulcer (within 3 months)",
                "html": "Active peptic ulcer (within 3 months)"
            },
            {
                "type": "cautions",
                "textContent": "acute pericarditis",
                "html": "acute pericarditis"
            },
            {
                "type": "cautions",
                "textContent": "anaemia",
                "html": "anaemia"
            },
            {
                "type": "cautions",
                "textContent": "aortic dissection",
                "html": "aortic dissection"
            },
            {
                "type": "cautions",
                "textContent": "cardiogenic shock",
                "html": "cardiogenic shock"
            },
            {
                "type": "cautions",
                "textContent": "discontinue if intra-aortic balloon pump necessary",
                "html": "discontinue if intra-aortic balloon pump necessary"
            },
            {
                "type": "cautions",
                "textContent": "discontinue if thrombolytic therapy necessary",
                "html": "discontinue if thrombolytic therapy necessary"
            },
            {
                "type": "cautions",
                "textContent": "discontinue immediately if serious or uncontrollable bleeding occurs",
                "html": "discontinue immediately if serious or uncontrollable bleeding occurs"
            },
            {
                "type": "cautions",
                "textContent": "discontiue if emergency cardiac surgery necessary",
                "html": "discontiue if emergency cardiac surgery necessary"
            },
            {
                "type": "cautions",
                "textContent": "elderly",
                "html": "elderly"
            },
            {
                "type": "cautions",
                "textContent": "faecal occult blood",
                "html": "faecal occult blood"
            },
            {
                "type": "cautions",
                "textContent": "haematuria",
                "html": "haematuria"
            },
            {
                "type": "cautions",
                "textContent": "haemorrhagic retinopathy",
                "html": "haemorrhagic retinopathy"
            },
            {
                "type": "cautions",
                "textContent": "low body-weight",
                "html": "low body-weight"
            },
            {
                "type": "cautions",
                "textContent": "major surgery within 3 months (avoid if within 6 weeks)",
                "html": "major surgery within 3 months (avoid if within 6 weeks)"
            },
            {
                "type": "cautions",
                "textContent": "organ biopsy or lithotripsy within last 2 weeks",
                "html": "organ biopsy or lithotripsy within last 2 weeks"
            },
            {
                "type": "cautions",
                "textContent": "puncture of non-compressible vessel within 24 hours",
                "html": "puncture of non-compressible vessel within 24 hours"
            },
            {
                "type": "cautions",
                "textContent": "risk of bleeding (within 3 months)",
                "html": "risk of bleeding (within 3 months)"
            },
            {
                "type": "cautions",
                "textContent": "severe heart failure",
                "html": "severe heart failure"
            },
            {
                "type": "cautions",
                "textContent": "severe trauma within 3 months (avoid if within 6 weeks)",
                "html": "severe trauma within 3 months (avoid if within 6 weeks)"
            },
            {
                "type": "cautions",
                "textContent": "traumatic or protracted cardiopulmonary resuscitation within last 2 weeks",
                "html": "traumatic or protracted cardiopulmonary resuscitation within last 2 weeks"
            },
            {
                "type": "cautions",
                "textContent": "uncontrolled severe hypertension",
                "html": "uncontrolled severe hypertension"
            },
            {
                "type": "cautions",
                "textContent": "vasculitis",
                "html": "vasculitis"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (tirofiban).\n\nConcomitant drugs that increase risk of bleeding (including within 48 hours of thrombolytic administration).",
                "html": "<p>Appendix 1 (tirofiban).</p><p>Concomitant drugs that increase risk of bleeding (including within 48 hours of thrombolytic administration).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Bleeding manifestations",
                        "html": "Bleeding manifestations",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fever",
                        "html": "fever",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "reversible thrombocytopenia",
                        "html": "reversible thrombocytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;no information available.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in mild to moderate liver disease.\n\nAvoid in severe liver disease&#8212;increased risk of bleeding.",
                "html": "<p>Caution in mild to moderate liver disease.</p><p>Avoid in severe liver disease&#8212;increased risk of bleeding.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Use half normal dose if eGFR less than 30 mL/minute/ 1.73 m2.",
                "html": "<p>Use half normal dose if eGFR less than 30&#8239;mL/minute/ 1.73&#8239;m<sup>2</sup>.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Increased risk of bleeding.",
                "html": "<p>Increased risk of bleeding.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor carefully if eGFR less than 60 mL/minute/1.73 m2.",
                "html": "<p>Monitor carefully if eGFR less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor platelet count, haemoglobin and haematocrit before treatment, 2&#8211;6 hours after start of treatment and then at least once daily.",
                "html": "<p>Monitor platelet count, haemoglobin and haematocrit before treatment, 2&#8211;6 hours after start of treatment and then at least once daily.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "For intravenous infusion (Aggrastat ), give continuously in Glucose 5% or Sodium chloride 0.9%. Withdraw 50 mL infusion fluid from 250 mL bag and replace with 50 mL tirofiban concentrate (250 micrograms/mL) to give a final concentration of 50 micrograms/mL.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Aggrastat</i>\n<tm tmtype=\"reg\"/>), give continuously in Glucose 5% or Sodium chloride 0.9%. Withdraw 50&#8239;mL infusion fluid from 250&#8239;mL bag and replace with 50&#8239;mL tirofiban concentrate (250&#8239;micrograms/mL) to give a final concentration of 50&#8239;micrograms/mL.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77073",
                "label": "Infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77064",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78144",
                "label": "Acute coronary syndromes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78186",
                "label": "Antiplatelet drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1018",
                "label": "Tirofiban",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77073",
                "label": "Infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77064",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}